Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tukysa
Pharma
Overall survival data blur Seagen's Tukysa-ADC path
Unlike the positive tumor progression signal, the Tukysa-Kadcyla regimen showed an increased risk of death at an interim analysis.
Angus Liu
Dec 6, 2023 8:15am
Seagen's breast cancer drug Tukysa boosts Roche's ADC
Aug 17, 2023 10:18am
Pfizer snaps up ADC cancer specialist Seagen for $43B
Mar 13, 2023 10:51am
Seagen's revenue up 25% in 2022 as growth drivers 'firing'
Feb 16, 2023 10:42am
Seagen's Tukysa snags FDA nod in colorectal cancer
Jan 19, 2023 4:12pm
Seagen's Tukysa picks up FDA priority review in Herceptin combo
Sep 20, 2022 10:59am
